These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 28840962)

  • 1. Biomarkers and therapeutic advances in glioblastoma multiforme.
    Sasmita AO; Wong YP; Ling APK
    Asia Pac J Clin Oncol; 2018 Feb; 14(1):40-51. PubMed ID: 28840962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adult Glioblastoma.
    Alexander BM; Cloughesy TF
    J Clin Oncol; 2017 Jul; 35(21):2402-2409. PubMed ID: 28640706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New molecularly targeted therapies for glioblastoma multiforme.
    Polivka J; Polivka J; Rohan V; Topolcan O; Ferda J
    Anticancer Res; 2012 Jul; 32(7):2935-46. PubMed ID: 22753758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma.
    Wang ZQ; Zhang MY; Deng ML; Weng NQ; Wang HY; Wu SX
    PLoS One; 2017; 12(9):e0184969. PubMed ID: 28931080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
    Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
    J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas.
    Regazzo G; Terrenato I; Spagnuolo M; Carosi M; Cognetti G; Cicchillitti L; Sperati F; Villani V; Carapella C; Piaggio G; Pelosi A; Rizzo MG
    J Exp Clin Cancer Res; 2016 Jul; 35(1):124. PubMed ID: 27476114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary gliosarcoma: the clinicopathological features and the development of a patient-derived xenograft model of gliosarcoma.
    Kiang KM; Chan AA; Leung GK
    BMC Cancer; 2021 Mar; 21(1):265. PubMed ID: 33706745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review of multifocal and multicentric glioblastoma.
    Li Y; Zhang ZX; Huang GH; Xiang Y; Yang L; Pei YC; Yang W; Lv SQ
    J Clin Neurosci; 2021 Jan; 83():71-76. PubMed ID: 33358091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting EGFRvIII for glioblastoma multiforme.
    Yang J; Yan J; Liu B
    Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of glioblastoma in biofluids.
    Figueroa JM; Carter BS
    J Neurosurg; 2018 Aug; 129(2):334-340. PubMed ID: 29053069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glioblastoma biomarkers from bench to bedside: advances and challenges.
    Farias-Eisner G; Bank AM; Hwang BY; Appelboom G; Piazza MA; Bruce SS; Sander Connolly E
    Br J Neurosurg; 2012 Apr; 26(2):189-94. PubMed ID: 22176646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 4-miRNAs signature predicts survival in glioblastoma multiforme patients.
    Yuan GQ; Wei NL; Mu LY; Wang XQ; Zhang YN; Zhou WN; Pan YW
    Cancer Biomark; 2017 Dec; 20(4):443-452. PubMed ID: 28869437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A practical review of prognostic correlations of molecular biomarkers in glioblastoma.
    Karsy M; Neil JA; Guan J; Mahan MA; Colman H; Jensen RL
    Neurosurg Focus; 2015 Mar; 38(3):E4. PubMed ID: 25727226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glioblastoma Multiforme: Fewer Tumor Copy Number Segments of the
    Lehrer S; Rheinstein PH; Rosenzweig KE
    Cancer Genomics Proteomics; 2018; 15(4):273-278. PubMed ID: 29976632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells.
    Wong ST; Zhang XQ; Zhuang JT; Chan HL; Li CH; Leung GK
    Anticancer Res; 2012 Jul; 32(7):2835-41. PubMed ID: 22753745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNAs as Multifaceted Players in Glioblastoma Multiforme.
    Mercatelli N; Galardi S; Ciafrè SA
    Int Rev Cell Mol Biol; 2017; 333():269-323. PubMed ID: 28729027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic markers for glioblastoma.
    Jung CS; Unterberg AW; Hartmann C
    Histol Histopathol; 2011 Oct; 26(10):1327-41. PubMed ID: 21870336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frontal glioblastoma multiforme may be biologically distinct from non-frontal and multilobar tumors.
    Paldor I; Pearce FC; Drummond KJ; Kaye AH
    J Clin Neurosci; 2016 Dec; 34():128-132. PubMed ID: 27593971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
    Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
    Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy.
    Motegi H; Kamoshima Y; Terasaka S; Kobayashi H; Yamaguchi S; Tanino M; Murata J; Houkin K
    Brain Tumor Pathol; 2013 Apr; 30(2):67-72. PubMed ID: 22752663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.